Scleroderma Lung Study III - Combining Pirfenidone With Mycophenolate
Status:
Active, not recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
A Phase II multi-center, double-blind, parallel group, randomized and placebo-controlled
clinical trial addressing the treatment of patients with active and symptomatic
Scleroderma-related interstitial lung disease (SSc-ILD).
Phase:
Phase 2
Details
Lead Sponsor:
Michael Roth
Collaborators:
Genentech, Inc. University of California, Los Angeles University of Michigan